How to Choose Dialysis Equipment

A procurement guide for hospital nephrology units, ESRD centers, ASCs, and home-HD programs navigating machine selection, water treatment, and total cost of ownership.

---

What this is and who buys it

Dialysis equipment is not a single product category — it is a family of distinct platforms that each perform renal replacement therapy through different mechanisms and for different patient populations. Hemodialysis (HD) delivery systems cycle blood through an extracorporeal circuit to remove uremic waste and excess fluid. Continuous renal replacement therapy (CRRT) machines do the same but at much slower flow rates, designed for hemodynamically unstable ICU patients who cannot tolerate standard four-hour sessions. Peritoneal dialysis (PD) cyclers take an entirely different approach, using the patient's peritoneal membrane as the filter and infusing dialysate into the abdomen — a modality most often managed at home. Supporting all in-center HD is water treatment infrastructure: reverse osmosis systems, carbon filtration, and distribution loops that convert municipal water into a fluid safe enough to contact the bloodstream across a semipermeable membrane.

Buyers span a wide range of settings. Free-standing ESRD dialysis centers — which account for the majority of U.S. chronic HD volume — prioritize throughput, disinfection speed, and CMS reporting integration. Hospital inpatient nephrology units need machines that can shift between acute HD and CRRT without duplicating capital. Ambulatory surgery centers with nephrology programs may need only a handful of stations. Home-health organizations or hospital home-HD programs are looking at compact, FDA-cleared platforms that a trained patient can operate independently four to seven times per week.

Purchase decisions are typically triggered by one of four events: a new facility opening, fleet aging beyond ten years, modality expansion (adding hemodiafiltration, or CRRT capability where none existed), or a CMS survey deficiency related to water quality compliance. In each case, the procurement decision is more complex than choosing a machine — it is choosing a clinical system that includes consumables, water treatment, staff training, and a multi-year service relationship.

---

Key decision factors

Modality breadth per platform. The central capital question is whether a single multi-modality device can cover intermittent HD, sustained low-efficiency dialysis (SLED), hemodiafiltration (HDF), and CRRT, or whether purpose-built single-modality units are better suited to your patient mix. Multi-modality machines can reduce capital outlay and fleet complexity, but they demand staff who are credentialed and competency-assessed across every mode — which carries its own training overhead.

Ultrafiltration control accuracy. For high-permeability systems under 21 CFR §876.5860, the machine must include a volumetric or gravimetric ultrafiltration controller. Before committing to a platform for hemodynamically unstable patients, pull the device's 510(k) labeling and confirm the UF accuracy tolerance — typically ±1% of the prescribed removal volume. Wider tolerances translate directly to higher risk of intradialytic hypotension in fragile patients [S1].

Water treatment infrastructure. This is the most frequently underestimated line item in a dialysis procurement. Every in-center HD facility requires a dedicated reverse osmosis loop meeting ANSI/AAMI RD52:2004 and the current ISO 23500-3:2019 standard [S3]. A 20-station facility needs an RO system producing approximately eight gallons per minute — and the water treatment equipment itself runs $30,000 to $150,000, entirely separate from machine cost. Vendors who quote machines without addressing RO compatibility and installation are presenting an incomplete scope.

Disinfection cycle time. Automated heat or chemical disinfection cycle duration has a direct, calculable impact on throughput. A machine requiring 60–90 minutes between patient sessions will support meaningfully fewer station turns per day than one completing disinfection in under 30 minutes. In a three-shift center running 18 sessions per station per week, this difference compounds quickly into revenue.

Consumable lock-in and per-treatment cost. Proprietary dialyzers, tubing sets, and concentrate cartridges are a binding long-term financial commitment, not a one-time consideration. The consumable cost per machine typically runs $2,000–$5,000 annually, and platforms with closed consumable ecosystems can price those items 30–50% above open-market equivalents. Always build a three-year total cost of ownership model before comparing capital prices.

EMR and data management integration. Confirmed HL7 or API connectivity to your ESRD data management platform and CROWNWeb reporting for CMS is not a nice-to-have — its absence shifts documentation burden to clinical staff and creates audit risk [S2]. Ask vendors for integration documentation, not promises.

Pediatric suitability. For hospitals treating pediatric patients, minimum prime volume (ideally below 50 mL) and minimum blood flow rates (as low as 10–20 mL/min) are hard specifications that must appear in the cleared labeling, not just in a sales sheet.

---

What it costs

Dialysis equipment pricing varies enormously by modality, platform generation, and whether water treatment infrastructure is included. Published list prices are rarely what large centers pay, and pricing for many OEM platforms is not publicly disclosed — so any budget model should be validated by formal RFQ against your specific volume and configuration.

• Entry ($10,000–$25,000): Older-generation or refurbished in-center HD machines; PD cyclers; basic home-HD platforms. Limited feature sets; verify firmware support lifecycle before committing.
• Mid-range ($25,000–$75,000): Current-generation in-center HD systems with HDF capability; entry-level CRRT platforms; RO system components for smaller facilities.
• Premium ($75,000–$200,000+): Full-featured CRRT machines with citrate anticoagulation management; multi-modality platforms; complete RO water treatment systems for larger centers; home-HD systems with remote monitoring.

---

Common use cases

Dialysis equipment gets deployed across a wider range of clinical environments than most procurement officers initially expect, and the right platform specification is highly context-dependent.

• Free-standing ESRD centers: High-volume in-center HD running three sessions per day, three days per week per patient. Throughput, disinfection speed, and CROWNWeb-compatible data export are the dominant procurement criteria.
• Hospital ICUs (CRRT-specific): Hemodynamically unstable AKI patients requiring 24-hour continuous therapy; platform selection should include evaluation of built-in anticoagulation management features (citrate versus heparin protocols) and ICU nursing competency requirements.
• Hospital inpatient nephrology units: Mixed acute IHD and CRRT caseloads; multi-modality platforms that convert between modes can serve both the nephrology floor and the ICU from a single fleet.
• Home hemodialysis programs: Compact, FDA-cleared units for patient self-administration; only approximately 2.4% of U.S. ESRD patients currently use home HD, but the modality is growing and requires CMS-certified training infrastructure and remote monitoring capability.

---

Regulatory and compliance

Conventional hemodialysis delivery systems are Class II medical devices under 21 CFR §876.5820 (product code KDI); high-permeability systems fall under 21 CFR §876.5860. Both classifications require 510(k) premarket clearance demonstrating substantial equivalence to a predicate device [S1]. Every machine sold for U.S. use should have a specific K-number you can verify independently at FDA's 510(k) database. Peritoneal dialysis equipment is governed by ANSI/AAMI/IEC 60601-2-39:2018, and all networked machines must comply with IEC 60601-1 general electrical safety standards as well as FDA's 2023 cybersecurity guidance for premarket submissions.

On the water quality side, CMS Conditions for Coverage at 42 CFR Part 494, §494.40 mandate that dialysis facilities maintain water and dialysate quality meeting ANSI/AAMI RD52:2004 standards [S2]. The current gold standard, however, is the ISO 23500 series (parts 1–5, adopted by AAMI between 2019 and 2020), which covers water quality, concentrates, and dialysis fluid specifications in more detail than the earlier ANSI/AAMI documents [S3]. Vendor documentation that references only the superseded RD52 without ISO 23500 alignment is a gap worth flagging during evaluation. Chlorine levels post-carbon filtration must remain below 0.5 mg/L free chlorine and 0.1 mg/L chloramines per 42 CFR §494.40(b)(2).

---

Service, training, and total cost of ownership

Installing a full in-center HD system is a construction project, not a delivery. RO plumbing, distribution loop construction, drain connections, and dedicated 20-amp GFI circuits per station require four to twelve weeks of facility preparation before machines arrive. CRRT units in ICUs are simpler — typically standard power and IV pole mounting — but the clinical infrastructure around them (nursing competency, consumable stock, alarm response protocols) takes longer to build.

Staff training is mandatory under CMS Conditions for Coverage, and manufacturer-led on-site training typically runs two to five days per cohort. Biomedical technicians require dialysis-specific training that goes well beyond general biomed certification, covering conductivity calibration, pressure transducer verification, blood leak detector testing, and water system bacteriology [S4]. Preventive maintenance intervals run every 1,000 hours of use or quarterly, whichever comes first, with an annual comprehensive PM including electrical safety inspection.

For service contracts, buyers have three realistic options: OEM contracts, third-party dialysis service organizations, and in-house biomed. OEM contracts carry premium pricing but offer guaranteed response times and OEM-sourced parts. Third-party specialized dialysis service organizations can reduce cost by 20–40% relative to OEM contracts, though parts sourcing for newer platforms may be slower. Large networks running 20 or more stations may justify hiring a dedicated dialysis biomed technician — a role typically compensated at $60,000–$85,000 annually — rather than paying $3,000–$8,000 per machine per year for an OEM contract. Expected service life for in-center HD machines is 10–15 years with consistent PM; CRRT machines in high-utilization ICUs typically require replacement at 7–10 years.

---

Red flags to watch for

Any vendor unable to supply a specific FDA 510(k) K-number for each model — one you can look up yourself at accessdata.fda.gov — should be disqualified immediately. There is no acceptable explanation for the absence of this information.

Be wary of machine-only quotes that do not address RO system compatibility, installation, and qualification. The water treatment system is a regulatory requirement, not an accessory, and omitting it from the procurement scope creates a compliance gap that surfaces at the first CMS survey.

Proprietary consumable bundles that obscure per-treatment cost are a significant long-term financial risk. Demand a three-year TCO model itemizing consumables separately from capital; platforms with closed ecosystems can erase apparent capital savings within 18–24 months.

Finally, avoid any arrangement where a "general biomed handles it" answer is offered for dialysis-specific PM. Dialysis equipment has failure modes — water quality exceedances, conductivity drift, blood leak detector degradation — that require specialized competency. A facility with no dialysis-trained biomed and no dedicated service contract is a patient safety and survey risk.

---

Questions to ask vendors

1. What is the specific FDA 510(k) K-number for each machine model, and does the clearance explicitly cover all modalities — IHD, HDF, SLED, CRRT — we intend to use in our setting?
2. What is the ultrafiltration accuracy specification (±% of prescribed volume), and how is it validated at installation and during each annual PM cycle?
3. Does your water treatment system documentation reference ISO 23500-3:2019, and who is contractually responsible for qualifying the RO loop to AAMI action levels before first patient use?
4. What is the complete three-year total cost of ownership per station, itemizing capital cost, installation, service contract, consumables per treatment, and water treatment maintenance?
5. What is the disinfection cycle time between patient sessions, and what is the maximum daily station capacity in a three-shift operating model based on that cycle?
6. What is the OEM's committed end-of-service-life date for this model, and for how many years after that date will spare parts and firmware updates remain available?

---

Alternatives

The refurbished market for in-center HD machines is legitimate and active — platforms like the Fresenius 2008K and B. Braun Dialog+ appear regularly through secondary-market channels at 40–60% of new list price. The tradeoffs are shorter warranties (typically six to twelve months versus one to two years for new), potential firmware obsolescence, and narrower OEM service support. Refurbished is a reasonable option for stable chronic HD fleets with experienced biomed support; it is not advisable for CRRT platforms, where firmware and algorithm updates carry direct clinical relevance.

On financing, capital leases spread machine cost over five to seven years, which can preserve cash for water treatment infrastructure and consumable inventory — often the smarter allocation for a new program. Operating leases structured as per-treatment pricing shift maintenance risk to the vendor but typically carry higher total cost and limit flexibility on consumable sourcing. For established high-volume centers, outright purchase combined with a third-party service contract generally yields a lower ten-year TCO than any lease structure. A two-vendor fleet strategy — one platform for chronic in-center HD, another for CRRT — adds procurement complexity but provides competitive leverage at contract renewal and limits exposure if a recall or supply disruption affects a single platform.

---

Sources

• FDA 510(k) for Dialysis Machine — 21 CFR §876.5820 and §876.5860 Classification Overview
• 42 CFR §494.40 — CMS Conditions for Coverage: Water and Dialysate Quality (eCFR)
• ISO 23500 Series: Ensuring Quality of Fluids for Hemodialysis and Related Therapies — AAMI Biomedical Instrumentation & Technology
• Challenges in Maintaining Hemodialysis Equipment — AAMI Biomedical Instrumentation & Technology